U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07564128) titled 'Infection Surveillance of R/R Multiple Myeloma Patients Treated With Elranatamab as Clinical Practice in Italy' on April 27.
Brief Summary: The primary objective of this study is to measure the infection rate and presentation pattern in first 12 months of therapy with elranatamab as standard clinical practice in adult patients with Relapsed/Refractory Multiple Myeloma.
Study Start Date: Aug., 2026
Study Type: OBSERVATIONAL
Condition:
Multiple Mieloma
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Published by HT Digital Content Services with permission from Health Daily Digest....